{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T08:48:07Z","timestamp":1789289287221,"version":"build-2803163510"},"reference-count":17,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Amgen, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe treatment patterns of migraine patients in the Japan Medical Data Center (JMDC) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients aged \u226518 years with \u22651 inpatient or \u22652 outpatient migraine diagnoses, \u22651 outpatient diagnosis and \u22651 migraine-specific acute treatment (triptan or ergotamine), or \u22652 migraine-specific acute treatments from 1 May 2011 to 30 April 2014 were identified. Patients were required to be enrolled in a health plan for \u22651 year before and after the index date. The first migraine diagnosis or acute treatment defined the index date. Patients were stratified by the migraine treatments observed after the index date (i.e. migraine-specific acute treatment only [AT], prophylactic with or without migraine-specific acute treatment [PT], or no treatment [NT]) and described regarding the first migraine treatment regimen and subsequent treatment patterns during up to 1 year of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16,443 patients met the eligibility criteria (9873 AT, 3022 PT, and 3548 NT). AT patients had mean (SD) 10.3 (20.5) acute treatment days during 1-year follow-up, and 81.9% received triptans. When assessing the first migraine treatment regimen during follow-up in PT patients, 29.2% received prophylactic treatment only and 51.7% received both acute and prophylactic treatment. Calcium-channel blockers with or without concomitant triptans (34.4%) were the most common first regimen. Approximately 62.2% discontinued initial prophylactic treatment after an average of 61.2 days (SD\u2009=\u200965.3) of persistent treatment. Among discontinuers, 15.2% reinitiated original treatment and 7.0% switched treatment post-discontinuation within a year, while the remaining patients did not receive prophylactic therapy following discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among Japanese migraine patients, prophylactic use was low and associated with a high rate of discontinuation following a brief treatment period. Many patients reinitiated or switched treatment following discontinuation, while a significant proportion of patients remained discontinued from prophylactic therapy, suggesting a high unmet need.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0333102419851855","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T11:24:26Z","timestamp":1559388266000},"page":"1518-1534","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":57,"title":["Treatment patterns and characteristics of patients with migraine in Japan: A retrospective analysis of health insurance claims data"],"prefix":"10.1177","volume":"39","author":[{"given":"Juliana L","family":"Meyers","sequence":"first","affiliation":[{"name":"Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L","family":"Davis","sequence":"additional","affiliation":[{"name":"Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Lenz","sequence":"additional","affiliation":[{"name":"Global Development, Amgen, Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Saitama International Headache Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xue","sequence":"additional","affiliation":[{"name":"Global Safety, Amgen, Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"key":"bibr1-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1111\/head.12505_2"},{"key":"bibr2-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr3-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"bibr4-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00599.x"},{"key":"bibr5-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"bibr6-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1701015.x"},{"key":"bibr7-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04004.x"},{"key":"bibr8-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.02046.x"},{"key":"bibr9-0333102419851855","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.53.1228"},{"key":"bibr10-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02185.x"},{"key":"bibr11-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d0c"},{"key":"bibr12-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"bibr13-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60828-3"},{"key":"bibr14-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.01.006"},{"issue":"16","key":"bibr15-0333102419851855","volume":"86","author":"Lenz R","year":"2016","journal-title":"Neurology"},{"key":"bibr16-0333102419851855","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0113-0"},{"key":"bibr17-0333102419851855","unstructured":"Japan Statistics Bureau. Ministry of Internal Affairs. Employed persons by age, industry (Table\u00a011), http:\/\/www.e-stat.go.jp\/SG1\/estat\/ListE.do?Iid=000001105914 (2012, accessed November 2013)."}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102419851855","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0333102419851855","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102419851855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:48:18Z","timestamp":1777387698000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0333102419851855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1177\/0333102419851855"],"URL":"https:\/\/doi.org\/10.1177\/0333102419851855","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}